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a b s t r a c t 
Background: Hydroxychloroquine (HCQ) was proposed as potential treatment for COVID-19. 
Objective: We set-up a multicenter Italian collaboration to investigate the relationship between HCQ therapy and 
COVID-19 in-hospital mortality. 
Methods: In a retrospective observational study, 3,451 unselected patients hospitalized in 33 clinical centers 
in Italy, from February 19, 2020 to May 23, 2020, with laboratory-confirmed SARS-CoV-2 infection, were ana- 
lyzed. The primary end-point in a time-to event analysis was in-hospital death, comparing patients who received 
HCQ with patients who did not. We used multivariable Cox proportional-hazards regression models with inverse 
probability for treatment weighting by propensity scores, with the addition of subgroup analyses. 
Results: Out of 3,451 COVID-19 patients, 76.3% received HCQ. Death rates (per 1,000 person-days) for patients 
receiving or not HCQ were 8.9 and 15.7, respectively. After adjustment for propensity scores, we found 30% 
lower risk of death in patients receiving HCQ (HR = 0.70; 95%CI: 0.59 to 0.84; E-value = 1.67). Secondary analy- 
ses yielded similar results. The inverse association of HCQ with inpatient mortality was particularly evident in 
patients having elevated C-reactive protein at entry. 
Conclusions: HCQ use was associated with a 30% lower risk of death in COVID-19 hospitalized patients. Within 
the limits of an observational study and awaiting results from randomized controlled trials, these data do not 
discourage the use of HCQ in inpatients with COVID-19. 
1. Introduction 1 
The aminoquinoline hydroxychloroquine (HCQ) has been exten- 2 
sively used in the treatment of malaria and is currently widely used 3 
to treat autoimmune diseases like rheumatoid arthritis (RA), systemic 4 
lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), due 5 
to its immunomodulatory and anti-thrombotic properties [1] . More re- 6 
cently, a promising role of HCQ has been suggested in viral infec- 7 
tions [2] , since it directly inhibits viral entry and spread in several in 8 
vitro and in vivo models. Due to these properties, HCQ has been used 9 
in Ebola virus disease [3,4] , human immunodeficiency virus (HIV) in- 10 
fection [5] , SARS-CoV-1 infection and the Middle East Respiratory Syn- 11 
drome (MERS) [ 6 , 7 ] and gained worldwide attention as a possible ther- 12 
apy in COVID-19 patients [8] . 13 
HCQ might inhibit the intracellular glycosylation of ACE 2, the re- 14 
ceptor used by the SARS-CoV-2 virus to enter the cells, resulting in a 15 
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reduced ligand recognition and internalization of the virus [7] and exert- 16 
ing a possible protective role in SARS-CoV-2 infection. Moreover, due to 17 
its immunomodulatory, anti-inflammatory and anti-thrombotic effects, 18 
HCQ could also modulate the severity of the disease. However, the exact 19 
mechanism for the potential benefit in COVID-19 is largely speculative 20 
[9] and might be counterbalanced by adverse effects, mainly cardiovas- 21 
cular [ 10 , 11 ], so that the net balance of this drug’s use remains to be 22 
established. 23 
The American Food and Drug Administration (FDA) allowed Chloro- 24 
quine (CQ) phosphate and HCQ to be provided to certain hospitalized 25 
patients because these drugs may possibly help patients with severe 26 
COVID-19 [12] . The European Medicines Agency (EMA) authorized the 27 
use of CQ and HCQ for COVID-19 in clinical trials or as emergency use 28 
[13] , while the Italian Drug Agency (AIFA) stated in this emergency 29 
phase that therapeutic use of HCQ might be considered in COVID-19 30 
patients, both in those with mild presentation managed at home and in 31 
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hospitalized patients [14] . In clinical practice, HCQ rather than chloro- 32 
quine has been used because of its more potent antiviral properties and 33 
better safety profile [15] . 34 
However, in the light of a recent publication [16] , that was later re- 35 
tracted [17] , on the lack of safety and efficacy of HCQ in the treatment 36 
for COVID-19 patients the Executive Group of the Solidarity Trial de- 37 
cided to implement a temporary pause of the HCQ arm within the trial 38 
as a precaution, while the safety data is being reviewed [18] . Similarly, 39 
the Italian drug Agency AIFA decided to suspend the authorization to 40 
use HCQ for COVID-19 treatment outside clinical trials [19] . 41 
Recent reviews of clinical trials or observational studies [20–42 
24] have reported insufficient and often conflicting evidence on the ben- 43 
efits and harms of using HCQ to treat COVID-19 and concluded that as 44 
such, it was impossible to determine the balance of benefits to harm. 45 
Until now, although several trials had been started on the use of CQ and 46 
HCQ in COVID-19, only few of them have been published [25] on small 47 
numbers of patients or on surrogate endpoints or in exposed subjects for 48 
prophylaxis use [26] . 49 
While waiting the results from ongoing randomized clinical trials 50 
(RCT) to define the efficacy in preventing hard endpoints of this treat- 51 
ment so widely used during the emergency phase of the COVID-19 pan- 52 
demic, powered retrospective observational studies performed in differ- 53 
ent geographical and disease conditions may still be useful to shed light 54 
on this debate. Two retrospective observational studies, both conducted 55 
in the New York metropolitan region, did not report any significant as- 56 
sociation between HCQ use and rates of intubation or death [ 27 , 28 ]. 57 
No data are presently available from large cohorts of patients in Italy, 58 
which represents one of the most affected countries in terms of total 59 
deaths for COVID-19 in the world [29] . We undertook a multicenter Ital- 60 
ian collaboration [30] to investigate the relationship between underly- 61 
ing risk factors and COVID-19 outcomes, and to evaluate the association 62 
between different drug therapy and disease severity and/or mortality. 63 
We report here the results obtained in 3,451 hospitalized COVID -19 64 
patients receiving or not HCQ treatment. 65 
2. Material and methods 66 
2.1. Setting 67 
This national retrospective observational study was conceived, co- 68 
o  69 
I  70 
e  71 
(  72 
p  73 
I  74 
p  75 
t  76 
t  77 














hospitalization was retrospectively captured. Maximum clinical sever- 92 
ity observed was classified as mild pneumonia; or severe pneumonia; or 93 
acute respiratory distress syndrome (ARDS) [31] . Specifically, we ob- 94 
tained the following information for each patient: hospital; date of ad- 95 
mission and date of discharge or death; age; sex; the first recorded inpa- 96 
tient laboratory tests at the entry (creatinine, C-reactive protein); past 97 
and current diagnoses (myocardial infarction, heart failure, diabetes, 98 
hypertension, respiratory disease and cancer) and current drug thera- 99 
pies for COVID-19 – HCQ, lopinavir/ritonavir or darunavir/cobicistat, 100 
remdesevir, tocilizumab or sarilumab, corticosteroids, heparin, and for 101 
comorbidities (insulin, anti-hypertensive treatments, aldosterone recep- 102 
tor antagonists, diuretics, statins, sacubitril/valsartan). A diagnosis of 103 
pre-existing cardiovascular disease was based on history of myocar- 104 
dial infarction or heart failure. Chronic kidney disease was classified 105 
as: stage 1: kidney damage with normal or increased glomerular fil- 106 
tration rate (GFR) ( > 90 mL/min/1.73 m 2 ); stage 2: mild reduction 107 
in GFR (60-89 mL/min/1.73 m 2 ); stage 3a: moderate reduction in 108 
GFR (45-59 mL/min/1.73 m 2 ); stage 3b: moderate reduction in GFR 109 
(30-44 mL/min/1.73 m 2 ); stage 4: severe reduction in GFR (15-29 110 
mL/min/1.73 m 2 ); stage 5: kidney failure (GFR < 15 mL/min/1.73 m 2 111 
or dialysis). For statistical analysis, stages 3a and 3b and stages 4 and 112 
5 were combined. GFR was calculated by the Chronic Kidney Disease 113 
Epidemiology Collaboration (CKD-Epi) equation. Patients were defined 114 
as receiving HCQ if they were receiving it at admission to hospital or 115 
received it during the follow-up period. According to the AIFA guidance 116 
[14] , HCQ was administered at dose of 400 mg x 2/day or x4/day the 117 
first day, and 200 mg x 2/day from the second day onwards for at least 118 
5 to a maximum of 10 days, according to the clinical evolution of the 119 
disease. 120 
2.3. Statistical analysis 121 
The study index date was defined as the date of hospital admission. 122 
Index dates ranged from February 19, 2020 to May 23, 2020. The study 123 
end point was the time from study index to death. The number of pa- 124 
tients who either died, or had been discharged alive, or were still admit- 125 
ted to hospital as of May 29, 2020, were recorded, and hospital length of 126 
stay was determined. Patients alive had their data censored on the date 127 
of discharge or as the date of the respective clinical data collection. Data 128 
were censored at 35 days of follow up in n = 330 (8.3%) patients with a 129 
follow up greater than 35 days. 130 
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t  146 rdinated and analysed within the CORIST Project (ClinicalTrials.gov
D: NCT04318418, 30]. The study was approved by the institutional
thics board of the Istituto di Ricovero e Cura a Carattere Scientifico
IRCCS) Neuromed, Pozzilli, and of all recruiting centres. Data for the
resent analyses were provided by 33 hospitals distributed throughout
taly (listed in the supplementary file). Acceptance to participate in the
roject or to provide data for the present analysis was not related to
he use of CQ/HCQ. Each hospital provided data from hospitalized pa-
ients who had a positive test result for the SARS-CoV-2 virus at any
ime during their hospitalization from February 19 to May 23, 2020.
he follow-up continued through May 29, 2020. 
.2. Data sources 
We developed a cohort comprising 3,971 patients with laboratory-
onfirmed SARS-CoV-2 infection in an in-patient setting. The SARS-CoV- status was declared based on laboratory results (polymerase chain re- 
ction on nasopharyngeal swab) from each participating hospital. Clin- 
cal data were abstracted at one-time point from electronic medical 
ecords or charts, and were collected using either a centrally designed 
lectronic worksheet or a centralized web-based database. Collected 
ata included patients’ demographics, laboratory test results, medica- 
ion administration, historical and current medication lists, historical 
nd current diagnoses, and clinical notes. In addition, specific infor- 









2 Of the initial cohort of 3,971 patients, 350 patients were excluded
rom the analysis because they had at least one missing data at baseline
r lost to follow up on HCQ use (N = 94), other drug therapies for COVID-
9 (n = 265), time to event (n = 59), outcome (death/alive, n = 8), COVID-
9 severity (n = 4), age (n = 4 with missing data and n = 2 with age < 18
ears) or sex (n = 2). Of the remaining 3,621 patients, 170 patients died
r were discharged within 24 hours after presentation, and were also
xcluded from the analysis. 
At the end, the analysed cohort consisted of n = 3,451 patients. In pa-
ients not included in the analysis (n = 520), as unique difference with the
nalysed group, the prevalence of diabetics (19.9% vs 14.8%, P = 0.0066)
nd, to a less extent, of men (62.3% vs 58.3%, P = 0.081) was higher. Out
f 3,541 patients, 295 (8.5%) had at least a missing value for covariates.
istribution of missing values was as follows: n = 178 for C-reactive pro-
ein; n = 69 for GFR; n = 74 for history of ischemic disease; n = 64 for his-
ory of chronic pulmonary disease; n = 51 for diabetes; n = 51 for hyper-
ension and n = 56 for cancer. We used multiple imputation techniques 147 
SAS PROC MI, n = 10 imputed datasets; and PROC MIANALYZE) to max- 148 
mize data availability. As sensitivity analysis, we also conducted a case- 149 
omplete analysis on 3,156 patients. 150 
Cox proportional-hazards regression models were used to estimate 151 
he association between HCQ use and death. Since multiple imputation 152 
as applied, the final standard error was obtained using the Rubin’s 153 
ule based on the robust variance estimator in Cox regression [32] . The 154 
roportional hazards assumption was assessed using weighed Schoen- 155 
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1  280 eld residuals, and no violation was identified. To account for the non-
andomized HCQ administration and to reduce the effects of confound-
ng, the propensity-score method was used. The individual propensities
or receiving HCQ treatment were assessed with the use of a multivari-
ble logistic-regression model that included age, sex, diabetes, hyperten-
ion, history of ischemic heart disease, chronic pulmonary disease, GFR,
-reactive protein, hospitals clustering and use of other drug therapies
or COVID-19 (lopinavir/ritonavir or darunavir/cobicistat, remdesivir,
orticosteroids, tocilizumab or sarilumab). Associations between HCQ
reatment and death was then appraised by multivariable Cox regres-
ion models with the use of propensity-score and further controlling
or hospitals clustering as random effect (frailty model). The use of a
railty model was chosen as suggested in [33] . The primary analysis
sed inverse probability by treatment weighting; the predicted proba-
ilities from the propensity-score model was used to calculate the sta-
ilized inverse-probability-weighting weight [34] . Stabilized weights
ere normalized so that they added up the actual sample size. Sec-
ndary analyses used propensity-score stratification (n = 5 strata) or mul-
ivariable Cox regression analysis or multivariable logistic regression
nalyses comparing death versus alive patients, or accounted for hos-
itals clustering via stratification or by robust sandwich estimator. Pre-
stablished subgroup analyses were conducted according to age or sex
f patients, degree of COVID-19 severity experienced during the hospi-
al stay, C-reactive protein at basal or other drug therapies for COVID-
9. Hospitals were clustered according to their geographical distribu-
ion, as illustrated in Table 1 . To quantify the potential for an un-
easured confounder to render apparent statistically significant hazard
atio non-significant, the E-value was calculated [35] . Analyses were
erformed with the aid of the SAS version 9.4 statistical software for
indows. 
. Results 
We included in the final current analyses 3,451 patients who were
ospitalized with confirmed SARS-CoV-2 infection at 33 clinical centres
cross Italy and either died, had been discharged, or were still in hospi-
al as of May 29, 2020. Of these patients, 2,634 (76.3%, range among
ospitals 53.2% to 93.6%) received HCQ. Timing of the first dose of
CQ after presentation to the hospital was 1 day for the large majority
f centres, and 2 to 3 days for the others. HCQ was administered in all
entres at the dose of 400 mg/day (in one centre however it was used at
he dose of 600 mg/day and in another at the dose of 600 mg/day but
nly in patients younger than 65 years). Duration of treatment ranged
rom 5 to 15 days (with 10 days as the modal value). The drug used was
CQ in all hospitals. 
Baseline characteristics according to HCQ use are shown in Table 1 .
atients receiving HCQ were more likely younger, men and had higher
evels of C-reactive protein and less likely had ischemic heart disease,
ancer or stages 3a or greater chronic kidney disease ( Table 1 ). Patients
eceiving HCQ more likely received another drug for COVID-19 treat-
ent (78.4%; lopinavir/ritonavir or darunavir/cobicistat, remdesevir,
ocilizumab or sarilumab, corticosteroids), in comparison with non-HCQ
atients (46.3%; P < 0.0001; Table 1 ). 
The unadjusted differences and difference s adjusted by propensity
cores between HCQ-treated and non-HCQ treated patients for each vari-
ble included in the propensity score are shown in Fig. 1 . All the pre-
reatment differences disappeared after adjustment by propensity score
eighting. The C-statistic of the propensity-score model was 0.74. 
.1. Primary outcome 
Out of 3,628 patients, 576 died (16.7%), 2,390 were discharged alive
69.3%) and 485 (14.1%) were still at the hospital. The median follow-
p was 14 days (interquartile range 8 to 22; range 2 to 35; 55,388
erson-days). Death rate (per 1,000 person-days) was 8.9 in HCQ and3 5.7 in non-HCQ patients ( Table 2 ). At univariable analysis, hazard ra-
io for mortality was 0.56 (95%CI: 0.47 to 0.67). In the primary mul-
ivariable analysis with inverse probability weighting according to the
ropensity score, HCQ use was associated with a 30% (95%CI: 16% to
1%) reduction in death risk ( Fig. 2 , Table 2 , E-value = 1.67). Secondary
ultivariable analyses yielded very similar results ( Table 2 ), as well as
ase-complete analyses restricted to the 3,156 patients without missing
ata ( Table 2 ). Considering secondary multivariable analyses overall,
R for mortality associated with HCQ ranged between 0.64 to 0.70,
ccording to type of analyses. Control of hospitals clustering with dif-
erent approaches also yielded similar results for the primary analysis
HR = 0.71, 95%CI: 0.59 to 0.85 when hospitals clustering was stratified
or and HR = 0.69, 95%CI: 0.54 to 0.88 with the robust sandwich esti-
ator). 
Subgroup analyses are presented in Table 3 . HCQ use remained con-
istently associated with reduced mortality in almost all subgroups. The
nverse association of HCQ with inpatient mortality is slightly more evi-
ent in women, elderly and in patients who experienced a higher degree
f COVID-19 severity. It was absent in-patient with C-reactive protein
 10 mg/L and clearly confined to patients with elevated C-reactive pro-
ein ( Table 3 ). 
. Discussion 
In a large cohort of 3,451 patients hospitalized for COVID-19 in 33
linical centers all over Italy, covering almost completely the period of
he hospitalization for COVID-19, the use of HCQ was associated with
 significant better survival. In-hospital crude death rate was 8.9 per
,000 person-day for patients receiving HCQ and 15.7 for those who
id not. After adjustment for known possible confounders, we observed
 30% reduction in the risk of death in patients receiving HCQ therapy
s compared with those who did not. 
Our findings provide clinical evidence in support of guidelines by
talian and several international Societies suggesting to use HCQ ther-
py in patients with COVID-19. However, the observed associations
hould be considered with caution, as the observational design of our
tudy does not allow to fully excluding the possibility of residual con-
ounders. Large randomized clinical trials in well-defined geographical
nd socio-economic conditions and in well-characterized COVID-19 pa-
ients, should evaluate the role of HCQ before any firm conclusion can
e reached regarding a potential benefit of this drug in patients with
OVID-19. 
Over 76% of patients received HCQ either alone or in combina-
ion with other drugs. They were more likely to be younger, men
nd with higher levels of C reactive protein at entry, while less likely
ad pre-existing comorbidities such as ischemic heart disease, cancer
nd severe chronic kidney disease, as compared to patients not receiv-
ng the drug. We adjusted our analyses for possible confounders, in-
luding age, sex, diabetes, hypertension, history of ischemic heart dis-
ase, chronic pulmonary disease, chronic kidney disease, C-reactive pro-
ein and additional treatments for COVID-19, and took into account
ossible differences across centres by either adjustment or stratifica-
ion. To minimize bias due to the observational design, we used dif-
erent analytical approaches aiming at creating an overall balance be-
ween comparison groups. Finally, we tried to limit bias due to miss-
ng data by using a multiple imputation approach, but in no case,
he result was changed. Despite all these precautions, we recognize
he possibility, however, of residual unmeasured confounders affecting
esults. 
Systematic reviews of small clinical trials had reported contrast-
ng results that were however scarcely reliable because of poor de-
igns [20–25] . The HCQ doses tested in a Chinese randomized clin-
cal trial [25] were approximately double as compared to that used
n our study (1200 mg vs 800 mg as loading dose, 800 mg vs 400
g as maintenance dose) for twice the time (14-21 days versus 7-
0 days). National guidelines in Italy suggest to use HCQ 200 mg
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General characteristics of COVID-19 patients
Hyd
Characteristic No (
Age -median (IQR-yr.) 73 (
Gender - no (%) 
Women 361 
Men 456 
Diabetes - no (%) 
No 633 
Yes 162 
missing data 22 (
Hypertension - no (%) 
No 378 
Yes 416 
missing data 23 (
Ischemic heart disease - no (%) 
No 610 
Yes 179 
missing data 28 (
Chronic pulmonary disease - no (%) 
No 666 
Yes 127 
missing data 24 (
Cancer - no (%) 
No 694 
Yes 101 
missing data 22 (
CKD stage ∗ ∗ - no (%) 
Stage 1 241 
Stage 2 281 
Stage 3a or stage 3b 180 
Stage 4 or stage 5 89 (
missing data 26 (
C Reactive Protein - no (%) 
< 1 mg/L 104 
1-3 mg/L 120 
> 3 mg/L 549 
missing data 44 (
Lopinavir or Darunavir use 
No 621 
Yes 196 









Clusters of hospitals 
Northern regions (except Milan) (n) 169 
Milan (m) 161 
Center regions (except Rome) (c)) 303 
Rome (r) 94 (
Southern regions (s) 90 (
(n) include hospitals of Novara, Monza, Vare
manitas Clinical and Research Hospital, Ce
Donato Milanese (Milano) and Cinisello Bal
Ravenna, Forlì, Firenze, Pisa, Chieti and Pesca
eases “L. Spallanzani ” and Università Cattoli
Pozzilli (Isernia), Acquaviva delle Fonti (Bari)
∗ Chi-square test. ∗ ∗ Stage 1: Kidney damage w
(GFR) ( > 90 mL/min/1.73 m 2 ); Stage 2: Mild
3a: Moderate reduction in GFR (45-59 mL/m
(30-44 mL/min/1.73 m 2 ); Stage 4: Severe red
Kidney failure (GFR < 15 mL/min/1.73 m 2 o
wice daily for at least 5-7 days in patients over 70 years and/or
ith co-morbidities (chronic obstructive pulmonary disease, diabetes,
ardiovascular disease) even with mild respiratory symptoms or with
adiographically documented pneumonia or in severe patients [36] .
he lower doses of HCQ used in our centers, as suggested by Italian4 eline, according to hydroxychloroquine use. 
loroquine 
7) Yes (N = 2,634) P-value unadjusted ∗ 
) 66 (55-77) < .0001 
< .0001 
) 940 (36.7%) 
) 1,694 (64.3%) 
0.71 
) 2,090 (79.3%) 
) 515 (19.6%) 
29 (1.1%) 
0.31 
) 1,294 (49.1%) 
) 1,312 (49.8%) 
28 (1.1%) 
< .0001 
) 2,190 (83.1%) 
) 398 (15.1%) 
46 (1.8%) 
0.21 
) 2,225 (84.5%) 
) 369 (14.0%) 
40 (1.5%) 
0.036 
) 2,338 (88.8%) 
) 262 (9.9%) 
34 (1.3%) 
< .0001 
) 970 (36.8%) 
) 991 (37.6%) 
) 487 (18.5%) 
 143 (5.4%) 
43 (1.6%) 
0.0003 
) 256 (9.7%) 
) 301 (11.4%) 
) 1,943 (73.8%) 
134 (5.1%) 
< .0001 
) 1,203 (36.7%) 
) 1,431 (64.3%) 
< .0001 
) 2,160 (82.0%) 
474 (18.0%) 
0.0015 
) 2,551 (96.9%) 
83 (3.1%) 
< .0001 
) 1,655 (62.8%) 
) 979 (37.2%) 
< .0001 
) 616 (23.4%) 
) 525 (19.9%) 
) 747 (28.4%) 
 390 (14.8%) 
 356 (13.5%) 
avia, Cremona and Padova; (m) include Hu- 
ardiologico Monzino, and hospitals of San 
 (Milano); (c) include hospitals of Modena, 
) include National Institute for Infectious Dis- 
 Sacro Cuore; (s) include hospital of Napoli, 
ia, Taranto, Catanzaro, Catania and Palermo 
ormal or increased glomerular filtration rate 
tion in GFR (60-89 mL/min/1.73 m 2 ); Stage 
3 m 2 ); Stage 3b: Moderate reduction in GFR 
n in GFR (15-29 mL/min/1.73 m 2 ); Stage 5: 
ysis). 
fficial guidelines [ 19 , 36 ], may have been both more effective and
afer. 
Two recently published large observational studies, both from large
ospitals in New York City, showed no association between HCQ use
nd in-hospital mortality [ 27 , 28 ], and deserve specific discussion. In the
European Journal of Internal Medicine 000 (2020) 1–10 
Table 2 
Incidence rates and hazard ratios for death in COVID-19 patients, according to hydroxychloroquine use. 
Multiple imputation analysis (N = 3,451) 
Death (N = 576) Patient at risk (N = 3,451) Person-days Death Rate (x1,000 person-days) 
Hydroxychloroquine 
No- no. (%) 190 (23.3%) 817 (100%) 12,084 15.7 
Yes- no. (%) 386 (14.7%) 2,634 (100%) 43,304 8.9 
Hazard ratio for death (HCQ versus non HCQ) HR (95% CI) 
Crude analysis 0.56 (0.47 to 0.67) 
Multivariable analysis ∗ 0.70 (0.58 to 0.85) 
Propensity score analysis, inverse probability weighting ∗ ∗ ( primary analysis ) 0.70 (0.59 to 0.84) 
Propensity score analysis, stratification (n = 5 strata) ∗ ∗ 0.67 (0.56 to 0.81) 
Odds ratio for death (HCQ versus non HCQ) OR (95% CI) 
Propensity score analysis, inverse probability weighting ∗ ∗ 0.67 (0.54 to 0.82) 
Case Complete Analysis (N = 3,156) 
Death (N = 510) Patient at risk (N = 3,156) Person-days Death Rate (x1,000 person-days) 
Hydroxychloroquine 
No- no. (%) 170 (22.9%) 741 (100%) 11,050 15.4 
Yes- no. (%) 340 (14.1%) 2,415 (100%) 39,274 8.7 
Hazard ratio for death (HCQ versus non HCQ) HR (95% CI) 
Crude analysis 0.56 (0.46 to 0.67) 
Multivariable analysis ∗ 0.71 (0.59 to 0.86) 
Propensity score analysis, inverse probability weighting ∗ ∗ 0.64 (0.53 to 0.76) 
Propensity score analysis, stratification (n = 5 strata) ∗ ∗ 0.68 (0.56 to 0.82) 
Odds ratio for death (HCQ versus non HCQ) OR (95% CI) 
Propensity score analysis, inverse probability weighting ∗ ∗ 0.67 (0.54 to 0.82) 
Abbreviations: HR, hazard ratios; CI, confidence intervals. ∗ Controlling for age, sex, diabetes, hypertension, history of 
ischemic heart disease, chronic pulmonary disease, chronic kidney disease, C-reactive protein, lopinavir/ritonavir or 
darunavir/cobicistat, tocilizumab or sarilumab, remdesivir or corticosteroids use as fixed effects and hospitals clustering as 
random effect. ∗ ∗ Including hospitals clustering as random effect covariate. 
study of Geleris et al. [27] , the percentage use of HCQ was lower than in 291 
Italy; moreover, in both US studies [ 27 , 28 ] the drug was more frequently 292 
administered to patients with previous illnesses and a more severe pre- 293 
sentation of the disease. Our cohort included milder pneumonia patients 294 
than the US population, due to between-country differences in indica- 295 
tions to the drug for the beginning of therapy ( e.g., mild pneumonia in 296 
Italy versus only severe pneumonia and ARDS in the US). Concomitant 297 
use of other drugs for COVID-19 was very low in one study [27] and was 298 
not reported in the other study [28] . In our cohort, patients receiving 299 
HCQ were more likely treated with another drug for COVID-19 treat- 300 
F djuste  
t serva  
b
ig. 1. The unadjusted standardized differences and standardized differences a
he variables included in the propensity score. All differences for the matched oby reference lines. 
5 d by propensity scores between HCQ-treated and non-HCQ treated patients for
tions are within the recommended limits of –0.25 and 0.25, which are indicated
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Fig. 2. Survival curves according to hydroxychloroquine use. The curves are adjusted by propensity score analysis (inverse probability for treatment weighting) and 
hospital index as random effect, and are generated using the first imputed dataset. The other imputed datasets are similar and thus omitted. 
Table 3 
Hazard ratios for mortality according to hydroxychloroquine use in different subgroups. 

















Subgroups No. death/patient at r
Women 80/361 
Men 110/456 Age < 70 years 22/357 
Age ≥ 70 years 168/460 
Highest degree of COVID-19 severity experienced at hospital 
Mild pneumonia or less 28/424 
Severe pneumonia 80/253 
Acute respiratory distress syndrome 82/140 
Use of other COVID-19 treatmentsˆ 
No 101/439 
Yes 89/378 
C-Reactive Protein at basal ∗ ∗ 
< 10 mg/L 56/412 
≥ 10 mg/L 123/361 
Abbreviations: HR, hazard ratios; CI, confidence intervals; ∗ Propensi
pital clustering as random effect covariate; multiple imputed analysi
ˆLopinavir/ritonavir or darunavir/cobicistat or tocilizumab or sarilum
∗ ∗ Missing data for N = 178. Frequencies and hazard ratios are based o
C-reactive Protein; multiple imputed analysis (N = 3,451) yielded ver
ent (78.4%), in comparison with non-HCQ patients (46.3%). Anyway, 
ur findings are adjusted for concomitant other drugs use. 
While the US studies were confined to one hospital only or a defined 
elatively small area in the Country, our study included 33 hospitals 
istributed all over Italy, covering regions with a high number of cases 
nd a high intra-hospital mortality and regions with a lower burden 
f the disease. The participating Italian clinical centers have different 
ealthcare facilities, different size, specialization, and ownership, and 
herefore quite closely represent the real-life Italian approach to COVID- 
9. Moreover, they differed for the percentage of use of HCQ and for 
he rate of in-hospital mortality that ranged between 34.1 and 1.5 per 
,000 persons/day. To consider this variability, we adjusted the analy- 
is for recruiting center and performed a number of subgroup analyses. 
n all circumstances, the association between HCQ use and a reduced 















6 7) Hydroxychloroquine YES (N = 2,634) 
No. death/patient at risk HR (95% CI) ∗ 
116/940 0.63 (0.46 to 0.86) 
270/1,694 0.74 (0.60 to 0.93) 93/1,542 0.76 (0.50 to 1.16) 
293/1,092 0.68 (0.56 to 0.83) 
40/1,358 0.70 (0.41 to 1.18) 
172/764 0.76 (0.58 to 0.99) 
174/512 0.68 (0.52 to 0.90) 
64/570 0.63 (0.45 to 0.88) 
322/2,064 0.77 (0.61 to 0.99) 
125/1,138 1.23 (0.86 to 1.77) 
241/1,362 0.59 (0.47 to 0.73) 
ty score analysis, inverse probability weighting, including hos- 
s. 
ab or remdesivir or corticosteroids. 
n a case complete analysis (N = 3,273) without missing data for 
y similar results. 
erse association of HCQ with inpatient mortality was more evident in 316 
lderly, in patients who experienced a higher degree of COVID-19 sever- 317 
ty or especially having elevated C-reactive protein, suggesting that the 318 
nti-inflammatory potential of HCQ may have had more important role 319 
ather than its antiviral properties. HCQ, indeed, beside an antiviral ac- 320 
ivity, may have both anti-inflammatory and anti-thrombotic effects [8] . 321 
his can justify its effect in reducing mortality risk, since Sars-Cov-2 can 322 
nduce pulmonary microthrombi and coagulopathy, that are a possible 323 
ause of its severity [ 37 , 38 ] and the lack in preventing SARS-CoV-2 in- 324 
ection after exposure [26] 325 
Nevertheless, large randomized clinical trials on the efficacy of HCQ 326 
n hard end-points are still lacking and the largest observational study 327 
howing no effect in reducing mortality has been retracted [ 16 , 17 ], 328 
gencies have suspended clinical trials on the efficacy of HCQ on 329 
OVID-19 disease or have restricted its use only to patients included 330 
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in clinical trials, in the absence of an ample, serene and balanced dis- 331 
cussion at international level. 332 
Very recently, a large RCT has become available as a pre-print pub- 333 
lication [39] , reporting no beneficial effect of HCQ in patients hospital- 334 
ized with COVID-19. However, the dose of HCQ used in that trial was 335 
almost the double of that administered in our real life conditions. A re- 336 
duced mortality was also observed by other observational studies using 337 
low or intermediate doses of HCQ [ 40 , 41 ]. 338 
Moreover, in our study patients taking HCQ more frequently re- 339 
ceived other anti-COVID drugs, whose interaction in reducing mortality 340 
cannot be completely ruled-out. Of note, despite the higher dosage used, 341 
the RCT did not show any excess in ventricular tachycardia or ventric- 342 
ular fibrillation in the HCQ arm (39). 343 
Therefore, it will be very important to compare results of studies 344 
with different mode of use and doses of HCQ, different characteristics 345 
of treated and untreated patients and different academic or real-world 346 
conditions. 347 
4.1. Strengths and limitations 348 
A major strength of this study is the large, unselected patient sample 349 
from 33 hospitals, covering the entire Italian territory. Patient sampling 350 
covered all the overt epidemic period in Italy. Several statistical ap- 351 
proaches were used to overcome biases due to the observational nature 352 
of the investigation. 353 
This study has however, several recognized limitations. The study 354 
population pertains to Italy, and the results obtained may not be appli- 355 
cable to other populations with a possibly different geographical and 356 
socio-economic conditions and natural history of COVID-19. Due to the 357 
retrospective nature of the study, some parameters were not available 358 
in all patients, and all in-hospital medications might have been not fully 359 
recorded. Moreover, although guidelines on the use of HCQ in COVID- 360 
19 patients had been published in Italy since the first phase of the pan- 361 
demic, individual centers could have deviated from recommendations 362 
and used different doses or treatment schemes. We have no information 363 
on the HCQ doses used individually nor of their possible association with 364 
azithromycin. Moreover, adverse events possibly related to drug therapy 365 
were not collected, thus we cannot exclude bias due to therapy inter- 366 
ruption because of side effects; we do not know whether some deaths 367 
could have been due to cardiovascular complications of HCQ. However, 368 
recent data on Italian wards showed that COVID-19 patients receiving 369 
HCQ and azithromycin had a QTc-interval longer than before therapy, 370 
but did not experience, during their hospital stay, any arrhythmic com- 371 
plications, such as syncope or life-threatening ventricular arrhythmias 372 
[42] , a finding also reported by the RCT mentioned above (39). 373 
Finally, the possibility of unmeasured residual confounding cannot 374 
be completely ruled-out. However, the E-value for the lower boundary 375 
of the confidence interval of our main result is 1.67, indicating that the 376 
confidence interval could be moved to include the null by a strong un- 377 
measured confounder associated with both HCQ treatment and death 378 
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